News

These new data provide additional evidence for a range of benzene concentrations detected by in over-the-counter drug products with BPO maintained at room temperature.

A recent study shows the FDA's black-box warnings on antidepressants have led to decreased usage among youth, with an increase in suicide attempts and deaths observed.

This September 2024 month in review spotlights our top coverage of recent nephrology pipeline updates, guidelines, and research.

Anemia is frequently observed in primary care patients with HF and is linked to worse prognosis and comorbidities, including cancer.

The decision by the FDA follows an announcement by Biofrontera that there were no safety issues found following the submission of the medication’s supplemental New Drug Application.

In this Month in Review, we highlighted some of the most notable stories covered in the dermatology space during September 2024.

Test your knowledge of the phase 3 MAESTRO-NASH trial supporting resmetirom (Rezdiffra)’s FDA accelerated approval for MASH with this quiz.

Our September 2024 monthly recap in endocrinology spotlights regulatory updates, new guidelines, and the latest episodes of Diabetes Dialogue.

New data reports a notably heightened risk of atopic dermatitis in patients with prurigo nodulais compared with a control cohort.

A study of > 14,000 patients offers insights on real-world usage and characteristics of new rimegepant users, showing distinct patterns in acute vs. preventive treatment.

Patients taking GLP-1 RAs were more likely to show food retention and inadequate bowel preparation, even when the medications were held before the procedure.

A new post-hoc analysis has also revealed improvements in quality of life in patients’ caregivers.

Counting down the most impactful news at major medical meetings, it’s the HCPLive Five! This episode focuses on 5 key updates from Maui Derm NP+PA Fall 2024 in Nashville.

A study shows secukinumab clears skin lesions faster than ustekinumab in generalized pustular psoriasis, with improved responses observed by week 2.

A review of 5 highly anticipated FDA decisions expected by year-end, including acoramidis for ATTR-CM, olezarsen for FCS, sotagliflozin for T1D and CKD, and more.

Study findings highlight the individual and combined impact of smoking tobacco and drinking alcohol on achieving PASI75 after 8 weeks of treatment.

The approval is based on findings from BLUE-C, where Cologuard Plus demonstrated sensitivities of 95% for colorectal cancer and 43% for advanced precancerous lesions at 94% specificity.

An EADV 2024 study suggests dupilumab use during pregnancy is generally safe and may lower risks of preterm labor, gestational hypertension, and diabetes.

Crisugabalin at 40 mg/d or 80 mg/d significantly reduced daily pain in adults with postherpetic neuralgia, a phase 3 study found.

Further research is needed to understand the mechanism behind the link as antibiotic exposure is often necessary in care.

A small percentage of participants with psoriasis reported adequate adherence, with nearly half showing low adherence to phototherapy treatment.

These 28-week data on twice-daily ESK-001 highlight the drug’s safety and efficacy among patients with psoriasis.

Contrary to previous research, findings suggest no significant difference in infertility between patients with HS, other dermatological diseases, and healthy controls.

An elevated social vulnerability index score was linked to increased mortality among patients with SCD in the 5-year CDC WONDER database.

These data were presented at EADV 2024 by UCB, with presenters highlighting positive long-term efficacy findings for bimekizumab among patients with plaque psoriasis.

Triptans, including eletriptan and sumatriptan, offer better migraine relief than newer, more expensive drugs, suggesting they should be first-line treatments.

Gross hematuria after COVID-19 mRNA vaccination was more likely in females, patients with IgAN/IgAV, and after the second and third vaccine doses.

Taher Modarressi, MD, sits down with hosts to share tips and practical nuggets for cardiometabolic health specialists to optimize prescription and adherence to newer therapies.